Effect of Erythropoiesis-Stimulating Agent Therapy in Patients Receiving Palliative Care of Chronic Kidney Disease

Completed

• Conditions: Anemia of Chronic Kidney Disease
• Interventions: Drug: Erythropoiesis-Stimulating Agent

• Registration Number: NCT03427801
• Lead Sponsor: Chinese University of Hong Kong

Brief Summary

An observational study to evaluate the effect of erythropoiesis-stimulating agents in treating anaemia of renal disease among adult patients receive palliative care instead of dialysis.

Detailed Description

Erythropoiesis-stimulating agent (ESA) has been commonly used to manage patients with end-stage renal disease receiving dialysis. The effects of ESA, however, are unclear. This study compares the result of erythropoiesis-stimulating agent (ESA) versus supportive care for chronic kidney disease patients receiving palliative care. The investigators design a retrospective observational study to evaluate the effect of erythropoiesis-stimulating agents in treating anaemia of renal disease among adult patients receive palliative care instead of dialysis. The primary objective is to assess whether ESA can reduce the transfusion burden and hospitalization.

Study Timeline

• Study Start: 2017-03-01
• Study First Submitted: 2018-02-03
• Study First Submitted QC: 2018-02-03
• Study First Posted: 2018-02-09
• Primary Completion: 2018-12-01
• Study Completion: 2018-12-30
• Status Verified: 2019-01
• Last Update Submitted: 2019-01-29
• Last Update Posted: 2019-01-31

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 78

Inclusion Criteria

• patients aged 18 years and older, who opted for ESA treatment during palliative renal care for > 360 days between January 1, 2014 and December 31, 2016

Read More

Exclusion Criteria

• patients who had dialysis or kidney transplant treatment

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Treatment Group	Erythropoiesis-Stimulating Agent	Chronic kidney disease patient receiving palliative care and erythropoiesis-stimulating agent

Primary Outcome Measures

Name	Time	Method
days of hospitalisation	one year
number of red cell transfusion	one year

Trial Locations

Locations (1)

Prince of Wales Hospital, Chinese University of Hong Kong; 🇭🇰 Shatin, New Territories, Hong Kong